Keeping Track: Bad News For Bristol And Lilly, Good News For TG Therapeutics
Executive Summary
The latest drug development news and highlights from our US FDA Performance Tracker.
You may also be interested in...
Keeping Track: Nektar Withdraws Oxycodegol NDA As Novel Submission Pileup Continues
The latest drug development news and highlights from our US FDA Performance Tracker.
TG’s Follicular Lymphoma Data Suggest Umbralisib Could Succeed In PI3K Delta Class
Overall survival data from a follicular lymphoma cohort of its umbrella NHL study indicate umbralisib could match other PI3K delta inhibitors’ efficacy with better safety/tolerability profile.
Keeping Track: A Duo Of RTOR Approvals, Thumbs Up For First Oral GLP-1 Treatment, And First Ebola Vaccine Nears US Market
The latest drug development news and highlights from our US FDA Performance Tracker.